Design control is the set of documented procedures, reviews, and records that govern how a medical device is designed, developed, and transferred to manufacturing. It exists because the FDA determined — after a series of device failures in the 1980s tied directly to design deficiencies — that many safety problems could be prevented if manufacturers followed a structured development process rather than designing ad hoc and testing late.

The original requirement appeared in 21 CFR Part 820.30, the Design Controls section of the Quality System Regulation (QSR), which took effect in 1996. On February 2, 2026, the FDA's Quality Management System Regulation (QMSR) replaced the QSR, aligning U.S. device requirements with ISO 13485:2016. Under the QMSR, design control requirements now map to ISO 13485 Clause 7.3 (Design and Development) rather than the prescriptive text of 820.30.

The substance of what FDA expects from design control programs has not changed significantly. The structure for demonstrating compliance has.

Who Must Follow Design Control Requirements

Under the old QSR's 820.30, design control applied to Class II and Class III devices and certain Class I devices. The QMSR and ISO 13485:2016 take a risk-based approach: design control requirements apply to any medical device where the design and development process could affect product safety, performance, or regulatory compliance.

In practice, this means most manufacturers of finished devices need documented design controls. Contract manufacturers who build to a customer-supplied design may be exempt from design control requirements for that specific product, but they must document the determination. The exemption is not assumed.

The Eight Elements of Design Control

Whether you are working under the old 820.30 or the current QMSR and ISO 13485:2016, the core elements of a design control system remain consistent.

Design and Development Planning requires a documented plan that identifies the activities required to complete the design, assigns responsibilities, and accounts for how the design interfaces with other products or systems. The plan must be updated as the design evolves. A static plan written at project kickoff and never revised is a documentation gap that FDA investigators note consistently.

Design Inputs are the documented requirements the device must meet. These include intended use, user needs, performance specifications, safety requirements, applicable standards, and regulatory requirements. Poorly defined inputs are the upstream cause of most design verification failures. If the inputs do not capture what the device actually needs to do, verification testing that confirms conformance to those inputs proves less than it appears to.

Design Outputs are the translated results of the design process: drawings, specifications, procedures, and software code. Each output must reference the input it satisfies, which is the foundation of design traceability. Under ISO 13485 Clause 7.3.4, design outputs must be in a form that allows verification against design inputs before release.

Design Review is a formal, documented examination at defined stages of the design process. It must include at least one individual who is not directly responsible for the design being reviewed. Design reviews evaluate whether the design meets its inputs, identify problems, and drive resolution before the project advances. Reviews that happen but are not documented — or that are documented as "no issues identified" without supporting records — generate audit findings during FDA inspections.

Design Verification confirms that the design output meets the design input. This is the "did we build it right" question. Verification typically involves testing, analysis, inspection, or comparison to a proven design. The verification protocol defines what will be tested, acceptance criteria, and sample sizes. When verification fails, the finding should feed back into the risk register and trigger a design change process.

Design Validation confirms that the finished device meets user needs and intended uses under actual or simulated use conditions. This is the "did we build the right thing" question. Validation must be performed on production-representative units. Validation on engineering prototypes does not satisfy the requirement. Under ISO 13485 Clause 7.3.6, software used in medical devices requires validation appropriate to its intended use and safety classification.

Design Transfer documents the process for moving the validated design into production. Transfer activities confirm that the production process can consistently produce a device that meets the design specifications. Transfer records connect the design outputs to the production documentation — drawings, work instructions, inspection criteria, and process parameters.

Design Changes require documented procedures for reviewing, approving, and implementing any change after design freeze. Under ISO 13485 Clause 7.3.9, changes must be evaluated for their effect on the complete device and on previously completed verification and validation activities. A change that affects a previously validated interface or safety-related function requires re-validation of the affected elements, not just re-testing.

What Changed Under FDA QMSR

The QMSR, effective February 2, 2026, incorporated ISO 13485:2016 by reference. This means FDA inspectors now evaluate design control compliance against ISO 13485 Clause 7.3 language rather than the specific text of 820.30.

Several practical differences follow from this shift.

The old 820.30 required a Design History File (DHF) — a compilation of records that describes the design history of a finished device. ISO 13485 Clause 7.3 does not use the term DHF, but FDA's QMSR final rule confirmed that FDA-specific requirements, including the DHF obligation, are maintained through supplemental requirements in the regulation. Manufacturers still need to maintain a DHF.

ISO 13485 Clause 7.3 introduces an explicit requirement for documented design and development inputs that include applicable regulatory requirements — a consideration for devices that need to comply with EU MDR, Canada's CMDR, or other international frameworks alongside U.S. requirements. For companies selling into multiple markets, design inputs that explicitly map to each applicable regulation simplify market-specific submission documentation.

The QMSR also strengthened the connection between design control and risk management. Under QMSR, ISO 14971 risk management outputs must be integrated into the design control process throughout development — not treated as a separate activity completed before design freeze. Design reviews must consider risk management outputs. Verification and validation activities must cover safety-critical functions identified in the risk analysis.

FDA Inspection Patterns for Design Controls

Design controls ranked as the second most frequently cited area in FDA device inspections in 2025, according to Hogan Lovells' September 2025 analysis of inspection trends. CAPA ranked first, and the two are closely connected: unresolved design control gaps frequently generate CAPAs, and CAPA investigations often surface design control deficiencies that were not previously documented.

The patterns FDA investigators find most often in design control programs:

Traceability gaps between design inputs and outputs are the single most common finding. Companies produce verification test reports but cannot show which input requirement each test was designed to verify. The traceability matrix either does not exist or was built after the fact and does not reflect the actual testing sequence.

Incomplete Design History Files are cited regularly, particularly in companies that manage design documentation across multiple systems — a PLM tool, a shared drive, and a paper archive. When an investigator requests the DHF and receives a partial compilation, the response "the rest is in the other system" is not sufficient. The DHF must be a coherent, accessible compilation.

Design changes processed outside the formal change control procedure appear in inspection records when companies make field corrections, software patches, or label changes without running those changes through the design control process. Under QMSR, any change to a previously validated design element requires documented evaluation and, where the change affects validated performance, re-validation.

Validation on non-representative units continues to be cited. Companies run final validation testing on hand-built or pre-production units and do not repeat or bracket the testing once manufacturing processes are finalized.

The Design History File: What Must Be in It

The DHF is not a single document. It is a compilation of records that, taken together, tells the complete story of how the device was designed and confirmed to meet its requirements.

A complete DHF includes the design and development plan, design input specifications, design output documentation, design review records, verification protocols and results, validation protocols and results, design transfer records, and all design change records from initial design through product release. Risk management records — per ISO 14971 — should also be referenced or included.

For companies managing DHFs in paper or disconnected electronic systems, the effort required to compile and present the DHF during an inspection is significant. The DHF must be produced quickly when requested. A two-day delay in assembling records creates its own impression during an inspection, separate from the content of the records themselves.

Managing Design Controls in an Electronic QMS

Design control in an electronic QMS connects planning documents, input specifications, output records, review sign-offs, verification and validation results, and change requests in a single traceable system. When a design input changes, the linked verification records receive an automatic notification. When a design change is submitted, the system identifies every downstream document that references the changed element.

This is the difference between traceability that exists as a spreadsheet maintained by one engineer and traceability that the system enforces by structure. During an FDA inspection, the ability to pull a complete, time-stamped, electronically signed DHF in minutes — rather than hours — directly affects how the inspection proceeds.

Cloudtheapp's Design Controls application connects inputs, outputs, reviews, and change management into a single workflow with full audit trail. Verification and validation records link directly to the design inputs they address. Request a demo at cloudtheapp.com/demo/ to see how the system handles DHF compilation and design change traceability.

The Inspection Question You Want to Be Ready For

FDA investigators ask one question in almost every device inspection that involves design controls: "Can you show me the traceability from your design inputs to your verification testing?"

Companies that answer this by opening a spreadsheet and scrolling through rows are spending inspection time explaining gaps. Companies that answer it by opening a QMS and pulling a linked traceability matrix in 30 seconds are moving on to the next question.

The design control requirement has not changed materially under QMSR. What the QMSR changed is the framework language and the explicit integration of risk management throughout the design process. For companies already running a mature ISO 13485 design control program, the transition to QMSR compliance is largely administrative. For companies that built their design control system around the specific text of 820.30 and never updated it to align with ISO 13485, there are substantive gaps to address before the next FDA Form 483 arrives.

This post created by and appeared first on Cloudtheapp

TLDR

Compliance activity means your team is completing required tasks: closing CAPAs, updating SOPs, logging training. Inspection readiness means your organization can demonstrate control, explain every decision, and respond to a regulatory authority with confidence on any given day. Most quality teams confuse the two. The distinction is consequential: FDA warning letters jumped 50% in 2025, and the majority of them were issued to companies with active compliance programs. Having a quality management system and being ready for inspection are two different states of organizational maturity.

The Confusion That Costs Companies Inspections

The phone rings. The FDA is at the front desk. For most quality teams, the first instinct is to run a status check on open CAPAs, pull training records, and alert the document control team.

That scramble is the problem.

A company that genuinely maintains inspection readiness does not scramble. Their records are complete, their data is current, their teams know how to respond, and their quality indicators are already telling the right story. The inspection is an event they prepared for continuously, not a crisis they react to.

Regulated companies across pharmaceuticals, medical devices, biotechnology, and manufacturing spend enormous effort on compliance activity every week. They write SOPs, conduct audits, execute training plans, and generate documentation. Yet when an inspector arrives, they receive FDA Form 483 observations. The gap between compliance activity and inspection readiness explains why.

What Compliance Activity Actually Means

Compliance activity refers to the set of tasks, procedures, and documentation requirements that a regulated organization must perform to maintain its quality system in technical adherence to regulatory standards.

It includes:

• Completing and closing CAPAs within required timeframes
• Maintaining training completion records
• Reviewing and approving documents on schedule
• Conducting required internal process audits
• Recording deviations and investigating out-of-specification results
• Submitting required reports to regulatory bodies

Compliance activity is necessary. Without it, a quality system is not functional. But compliance activity answers a binary question: did we do the required thing? It does not answer: does our quality system actually work, and can we prove it?

When a regulatory inspector reviews your CAPA system, they do not only ask whether CAPAs were closed. They ask whether the right root cause was identified, whether the action actually addressed the problem, whether recurrence was checked, and whether the team can articulate the logic behind every decision. Compliance activity produces records. Inspection readiness produces demonstrable control.

What Inspection Readiness Actually Means

Inspection readiness is a state, not an event. It describes an organization where quality systems are maintained in a condition suitable for regulatory review at all times, not reconstructed or cleaned up when a visit is scheduled.

True inspection readiness has five characteristics:

1. Documentation integrity at all times

Every record that could be requested in an inspection, SOPs, batch records, training logs, CAPA files, deviation reports, supplier qualification records, is current, retrievable, and carries a complete audit trail. There are no stale drafts awaiting approval and no gaps in version control.

2. Process knowledge across the team

Inspection readiness is not only a quality department responsibility. Operators, supervisors, and technical staff need to understand their processes well enough to answer inspector questions without rehearsed scripts. When an inspector asks a production technician why a specific control step exists, the answer cannot be "because the SOP says so." It needs to reflect genuine understanding.

3. A defensible quality story

Regulators evaluate whether your quality data tells a coherent, risk-based story. Why was this deviation risk-classified as major? Why was this CAPA extended? What does the trend in your OOS rate indicate, and what action did you take? Inspection-ready organizations can answer these questions with data, not improvisation.

4. Known and managed vulnerabilities

Every quality system has areas under improvement. An inspection-ready organization knows exactly where those areas are, has documented them, and has active plans to address them. Inspectors do not expect perfection. They expect transparency and control. Undisclosed vulnerabilities discovered during an inspection are far more damaging than self-identified ones.

5. Cross-functional accountability

Audit findings frequently cite quality system gaps that originate outside the quality department: in production, in IT, in procurement, or in leadership. Inspection readiness requires that quality accountability extends beyond the quality team to every function whose activities affect product quality and regulatory compliance.

Side-by-Side: The Critical Differences

The difference in regulatory outcomes between these two states is substantial. Companies with strong inspection readiness programs resolve FDA Form 483 observations on-site or within days and rarely escalate to warning letters. Companies relying solely on compliance activity often receive observations they did not anticipate and lack the real-time data to respond convincingly.

Why Compliance-Only Organizations Fail Inspections

Three patterns consistently explain why a technically compliant operation receives significant inspection findings.

The gap between paper and practice

An SOP exists for a process, but the way the team actually performs the step has drifted from the written procedure. Compliance activity keeps the SOP updated on its review schedule. Inspection readiness includes periodic verification that actual practice matches documentation, through internal process audits and direct floor observation.

The CAPA-as-activity trap

Closing CAPAs on time satisfies the compliance metric. But if the closed CAPA contains a generic corrective action, "retrained operator" or "revised procedure," without verified root cause or effectiveness confirmation, the inspector will note that your CAPA system lacks depth. Closing records is compliance activity. Closing with demonstrated effectiveness is inspection readiness.

Data integrity gaps

One of the most rapidly escalating areas of FDA scrutiny is data integrity, particularly the accuracy and completeness of the audit trail. Companies can have fully compliant data entry practices while having significant gaps in audit trail configuration: delayed timestamps, shared login credentials, or gaps in electronic signature control. These gaps are invisible during compliance reviews but become highly visible during inspections.

The Five Pillars of Sustained Inspection Readiness

Transitioning from compliance-reactive to inspection-ready requires structural changes to how quality is managed, not just tighter execution of existing processes.

Pillar 1: Always-on record readiness

Move from periodic record reviews to continuous maintenance. Every document in your controlled system should be approved, current, and retrievable within minutes. This requires a document management system with automated expiry alerts, workflow-driven approvals, and clear version control governance.

Pillar 2: Living inspection plan

Maintain a current inspection plan that assigns responsibilities, defines the inspection team and back room support, maps document retrieval procedures, and outlines the protocol for inspector questions and requests. This plan should be reviewed quarterly and tested annually through mock inspections.

Pillar 3: Real-time quality metrics

Inspection-ready organizations know their quality story before the inspector does. They maintain live dashboards showing CAPA status, overdue training, open deviations, and OOS trends. When asked about any indicator, the quality manager can pull the data immediately and explain the trend and the action taken.

Pillar 4: CAPA depth over CAPA velocity

Shift the incentive structure in your CAPA system from closing fast to closing correctly. This means requiring verified root cause documentation, defined effectiveness check criteria, and a scheduled recurrence review before a CAPA closes. Velocity metrics have their place, but they should not override quality-of-closure standards.

Pillar 5: Cross-functional quality ownership

Hold regular cross-functional quality reviews, separate from management review, where production, engineering, procurement, and IT discuss open quality events affecting their functions. Inspection readiness must be shared accountability. Quality cannot own the outcome alone when the risks originate in other departments.

The Technology Gap in Inspection Readiness

One of the most consistent differentiators between inspection-ready organizations and compliance-reactive ones is the maturity of their quality management technology.

Companies relying on paper-based systems or disconnected spreadsheets for CAPA tracking, document control, and training management face a structural disadvantage: they cannot produce real-time data during an inspection. When an inspector requests the history of a specific deviation or asks for the training record of a specific operator, the answer "we need to pull that together" signals exactly the kind of lack of control that generates observations.

Cloudtheapp's AI-powered QMS platform is purpose-built for the type of continuous, real-time quality control that genuine inspection readiness requires. Every quality event, from CAPA and deviations to training records and supplier qualifications, lives in a single validated platform with complete audit trails and role-based access controls. When an inspector asks a question, the answer is three clicks away, not three hours.

The platform's built-in analytics give quality leaders the live quality indicators they need for continuous review, rather than manual compilation before each audit cycle. And because the system is FDA-validated and supports 21 CFR Part 11, ISO 13485, and ISO 9001 compliance requirements, it closes the data integrity gaps that most compliance-activity-only programs leave open.

From Compliance-Reactive to Inspection-Ready: A Practical Path

Transitioning to sustained inspection readiness does not require a complete overhaul of your quality system. It requires a shift in how you use what you already have.

Start by closing the documentation gaps: identify every record category that is not maintained in real time and set a remediation timeline. Then run a mock inspection focused not on whether your records exist, but on whether your team can explain, contextualize, and defend them.

Use the findings from that mock inspection to prioritize. For most organizations, the highest-impact areas are CAPA depth, data integrity controls, and cross-functional training on quality responsibilities.

Finally, put the technology in place that eliminates manual compilation from your quality workflow. Real-time visibility is the foundation of inspection readiness, and no team can maintain it without the right system.

The companies that perform best in regulatory inspections are not the ones that work hardest the week before the inspector arrives. They are the ones that made continuous readiness a daily operating standard.

Ready to see how Cloudtheapp helps regulated organizations close the gap between compliance activity and genuine inspection readiness? Request a demo today.

This post created by and appeared first on Cloudtheapp

TLDR: A product change notification (PCN) is a formal communication that tells affected internal and external stakeholders about an upcoming change to a product, component, material, or process before that change takes effect. In regulated industries like medical devices and pharmaceuticals, PCN is not optional. FDA QMSR, ISO 13485, and the EU MDR all require manufacturers to document, evaluate, and notify the right parties for qualifying changes. Gaps in the process, specifically late notifications and incomplete impact assessments, are among the most frequent findings during regulatory inspections.

What Is a Product Change Notification?

A product change notification is a structured, documented communication issued by a manufacturer or supplier to inform affected parties that a change to a product, material, component, labeling, or manufacturing process is planned or has occurred. The goal is to give recipients enough information and time to assess how the change affects their own operations, regulatory submissions, or product safety.

In regulated industries, the term often intersects with the process change notification concept, since many product changes originate in process or material modifications rather than purely in design.

PCNs serve two distinct purposes. Internally, they trigger a formal change control evaluation before any modification reaches production. Externally, they alert customers, regulators, contract manufacturers, and suppliers to changes that may affect their own compliance status or product performance.

The notification is typically accompanied by a description of the change, the rationale, affected part numbers or configurations, implementation timeline, and a statement of impact on safety, performance, and regulatory submissions.

Why Product Change Notification Matters in Regulated Industries

Regulated industries operate under a core principle: any change that could affect product safety, efficacy, or compliance requires documented review and approval before implementation. When that principle is not followed consistently, the consequences are serious.

FDA inspection data consistently ranks change control as one of the most frequently cited quality system deficiencies for medical device manufacturers. Unauthorized or inadequately controlled changes can trigger product recalls, FDA Form 483 observations, and warning letters. In the European market, undocumented changes to a certified device can invalidate its CE mark.

For QA Managers and Regulatory Affairs professionals, the PCN process is not a bureaucratic formality. It is the primary mechanism that keeps the organization's design history file, audit trail, and regulatory submissions accurate and current.

Regulatory Requirements for Product Change Notification

FDA QMSR and ISO 13485:2016

The FDA Quality Management System Regulation (QMSR), which became effective on February 2, 2026, harmonizes the CGMP requirements of 21 CFR Part 820 with ISO 13485:2016 by incorporating the international standard by reference. This alignment effectively makes ISO 13485 design change control requirements enforceable under US federal regulation. (FDA.gov – QMSR)

ISO 13485:2016 Section 7.3.9 addresses design and development changes. It requires that organizations identify, document, review, verify, validate (as appropriate), and approve all design and development changes before implementation. Records of those activities must be maintained. The evaluation of design and development changes must include an assessment of the effect of the changes on constituent parts and product already delivered, including potential adverse effects on safety and performance.

Beyond design changes, ISO 13485 Section 4.1.6 requires that organizations communicate changes to external parties that may affect the conformity of outsourced processes or purchased products to requirements. This creates a clear obligation for suppliers who modify components used in medical devices to issue formal PCNs to their customers.

EU MDR: Articles 54, 55, and Annex IX

Under EU Regulation 2017/745 (EU MDR), manufacturers and notified bodies share responsibility for managing significant changes to certified devices.

Article 54 establishes the clinical evaluation consultation procedure for certain high-risk devices, specifically Class III implantable devices and Class IIb active devices intended to administer or remove a medicinal product. When a manufacturer proposes a change that could affect the clinical evaluation of such a device, the notified body must consult an expert panel before issuing or renewing a certificate. This means product changes in high-risk device categories carry a substantial regulatory overhead, requiring prior review by both the notified body and independent EU-appointed scientific experts.

Article 55 outlines the scrutiny mechanism for conformity assessments under Article 54. The notified body is required to notify competent authorities through the EUDAMED electronic system of certificates granted under this procedure. Any divergence between the notified body and the expert panel must be formally justified in the documentation.

Annex IX Section 2.4 sets the ongoing obligation for all certified manufacturers. It requires the manufacturer to inform the notified body of any plan for substantial changes to the QMS or the device range covered by the certificate. The notified body then assesses whether the changes require additional audits or re-certification.

For legacy devices still CE-marked under the former Medical Devices Directive, any change that constitutes a "significant change" to the design or intended purpose triggers the loss of legacy status and requires full MDR certification, as clarified through MDCG guidance.

Types of Changes That Require a PCN

Not every change requires a formal PCN, but organizations often fail because they underestimate which changes qualify. The following categories typically trigger a PCN requirement under FDA QMSR, ISO 13485, or EU MDR:

Design and engineering changes: Modifications to device dimensions, materials of construction, component specifications, software versions, or intended use. Even changes that appear cosmetic can affect biocompatibility, sterility, or mechanical performance.

Manufacturing process changes: Changes to manufacturing site, equipment, cleaning procedures, sterilization parameters, or process validation status. A change in a supplier's manufacturing process that the customer did not authorize is one of the most common sources of field failures.

Material and component changes: Substitution of a raw material, change in a component supplier, or modification to incoming inspection criteria. Under ISO 13485 and FDA QMSR, the impact of supplier changes on finished device safety must be formally evaluated.

Labeling changes: Updates to the instructions for use, labeling claims, intended patient population, or contraindications. Labeling changes often require regulatory submission updates.

Software changes: For software as a medical device (SaMD) or embedded device software, changes must follow a documented software change control procedure aligned with IEC 62304 and ISO 13485.

Regulatory submission changes: Any change that was part of a 510(k), PMA, or CE Technical File must be assessed to determine whether a new submission or notification to the regulatory authority is required before implementation.

Who Must Be Notified, and When

The recipient list for a PCN depends on the nature of the change, the regulatory classification of the product, and the contractual obligations in place.

Internal stakeholders who typically require notification include: Quality Assurance, Regulatory Affairs, Engineering, Manufacturing, Procurement, and Document Control. Each function evaluates the change from its own perspective. QA determines whether the change affects validated processes. RA determines whether the change triggers a regulatory submission. Engineering confirms the technical impact on the design history file.

External stakeholders who may require notification include: customers who incorporate the component or device into their own product, contract manufacturers or test labs involved in production, suppliers whose materials are affected, and regulatory bodies when submissions are impacted.

Timing requirements vary by regulatory framework. Under ISO 13485 and FDA QMSR, changes must be reviewed and approved before implementation. Under EU MDR Annex IX, the notified body must be informed of substantial QMS changes before they are executed so the notified body can determine whether additional audits are needed. Customer contracts in component supply relationships often specify minimum advance notice windows, typically 60 to 180 days, for material or manufacturing process changes.

Failure to notify external customers on time is a major source of supply chain disruption and field failures in the medical device industry, particularly when a component change affects a customer's 510(k) or Technical File without their awareness.

The Internal Change Control Process

A well-structured internal change control process is the foundation of a compliant PCN program. The process typically follows these stages:

1. Change request initiation: Any employee, supplier, or customer can initiate a change request. The request documents the proposed change, the reason for the change, and the affected products, processes, or documents. The request is formally logged in the change management system.

2. Impact assessment: A cross-functional team evaluates the change for its potential effects on product safety, performance, labeling, regulatory submissions, validation status, supplier qualifications, and the risk register. This is the most critical step in the process. An incomplete impact assessment is the primary cause of unauthorized changes reaching production.

3. Classification: The organization classifies the change by risk level. Minor changes may proceed through an expedited review. Major changes require full cross-functional review and may require regulatory consultation. Changes that affect the design history file, technical documentation, or an active regulatory submission require heightened scrutiny.

4. Approval: Based on the classification, designated reviewers approve or reject the change. For high-risk changes, approval may require sign-off from senior quality and regulatory leadership.

5. PCN issuance: For changes affecting external parties, a formal PCN document is prepared and distributed. The PCN includes the change description, rationale, affected part numbers, implementation date, and a summary of the impact assessment.

6. Implementation and verification: Approved changes are implemented according to a documented implementation plan. Post-implementation verification confirms that the change was executed correctly and that the expected outcomes were achieved.

7. Document update and closure: All affected documents, including SOPs, drawings, bills of materials, labeling, and quality records, are updated and released through document control. The change record is closed with full documentation of the actions taken.

The entire process must be traceable. Every action, every approval, and every notification must be captured in the audit trail to demonstrate compliance during inspections.

Common PCN Failures

Regulatory inspection findings and product recalls consistently point to the same failure patterns in PCN programs. Understanding these failure modes is the first step toward preventing them.

Late notification to affected parties: Many organizations issue PCNs after the change has already been implemented, or with insufficient advance notice for customers to complete their own impact assessment and regulatory evaluation. Late notification creates compliance gaps in the customer's quality system and can trigger field safety actions if the change affects a cleared or approved device.

Incomplete impact assessment: The most dangerous failure. When the impact assessment does not cover all affected functions, products, and regulatory submissions, changes slip into production without the necessary validation, document updates, or submission notifications. Incomplete assessments are a primary FDA 483 observation in medical device audits.

Inadequate change classification: Organizations that rely on informal or ad-hoc classification criteria frequently misclassify significant changes as minor ones, bypassing the full review process. This is especially common for software changes, material substitutions, and labeling updates.

Lack of a root cause investigation for change drivers: When a PCN is issued in response to a nonconformance or field complaint, the change must be linked to the underlying investigation. Organizations that manage PCN and deviation CAPA processes in separate, disconnected systems often lose this traceability.

Uncontrolled supplier changes: Many manufacturers discover that a critical component was modified by a supplier without a prior PCN only after a quality escape or field failure. This points to gaps in supplier quality management (SQM) agreements and incoming inspection programs.

Missing or incomplete audit trail: In manual or semi-automated systems, evidence of who was notified, when they acknowledged the notification, and what actions they took is often incomplete. During FDA and notified body inspections, the inability to produce a complete audit trail for a change can be as damaging as the change itself.

How eQMS Change Management Automates PCN Workflows

An enterprise QMS platform eliminates the fragmented, manual steps that cause PCN failures. Cloudtheapp's Change Management and Engineering Change applications give QA, RA, and Engineering teams a single, integrated environment to manage every stage of the PCN process, from initiation to closure.

Automated routing and notifications: When a change request is initiated in Cloudtheapp, the system automatically routes the record to the designated reviewers based on change type and risk classification. Every stakeholder receives a system-generated notification with a clear action required, eliminating the email-chain-based coordination that delays reviews and loses acknowledgments.

Integrated impact assessment: The platform links the change record directly to affected documents, risk records, supplier records, and regulatory submissions. Reviewers see all connected records in context, which makes it practical to conduct a complete impact assessment rather than a siloed one.

Configurable approval workflows: High-risk changes trigger multi-level approval workflows. Minor changes follow an expedited path. Organizations configure the routing logic using Cloudtheapp's no-code designer, without writing a single line of code, so the workflows reflect the actual regulatory requirements of each product line.

Connected Documents app: Once a change is approved, the Cloudtheapp Documents application automatically initiates the revision workflow for all affected controlled documents. Reviewers and approvers receive tasks directly in the platform. Released revisions are timestamped, version-controlled, and immediately accessible to all authorized users.

Integrated notification workflows for external PCNs: For changes that require external notification, Cloudtheapp supports the creation of formal PCN records that can be distributed to customers and suppliers with tracking of receipt and acknowledgment, all within the same audit trail as the internal change control record.

Complete, inspection-ready audit trail: Every action taken on a change record, every approval, every edit, every notification, and every document link, is captured automatically in the system audit trail. During an FDA inspection or notified body audit, the organization can produce a complete, chronological history of any change with a few clicks.

The result is a change management process that meets the documentation and traceability requirements of FDA QMSR, ISO 13485, and EU MDR without the administrative burden that typically slows engineering teams.

Build a PCN Process That Holds Up Under Inspection

A product change notification is only as strong as the process behind it. Organizations that rely on spreadsheets, shared drives, and email chains for change control consistently produce incomplete documentation, late notifications, and disconnected audit trails. These are exactly the findings that FDA investigators and notified body auditors look for.

A purpose-built eQMS platform removes the friction. With Cloudtheapp's Change Management, Engineering Change, and Documents applications working as an integrated system, quality and regulatory teams get full visibility into every change from request to closure, with the automated notifications and audit trail evidence needed to demonstrate compliance.

Request a demo at cloudtheapp.com and see how Cloudtheapp can bring your PCN process into a fully validated, audit-ready change control system.

This post created by and appeared first on Cloudtheapp

TLDR

ISO 9001:2026 is an evolutionary revision of ISO 9001:2015, expected for publication in September 2026. The Draft International Standard (DIS) was published on August 27, 2025, and received a 97% approval vote from ISO member countries in December 2025. Key confirmed changes include mandatory climate change consideration in Clause 4.1, expanded leadership duties around quality culture and ethical behavior in Clause 5.1.1, a restructured risk and opportunity management clause, and a new awareness requirement in Clause 7.3. The core requirements of the standard stay intact. ISO 9001:2015 certifications remain fully valid until the transition deadline of September 2029, and the first ISO 9001:2026 certificates will not be issued before mid-2027. Quality teams that act now, rather than waiting, will be best positioned for a smooth, low-disruption transition.

What Is ISO 9001:2026?

ISO 9001:2026 is the sixth edition of ISO 9001, the world's most widely adopted Quality Management System standard. It will replace ISO 9001:2015 upon publication, which is targeted for September 2026. The revision is developed by ISO Technical Committee ISO/TC 176, Subcommittee 2 (SC 2), which oversees quality systems and quality assurance.

The revision process formally began in July 2023, following a reversal of a 2021 decision to leave the standard unchanged. Since then, the process has moved through two Committee Drafts, a Draft International Standard, and is now approaching the Final Draft International Standard (FDIS) phase. Technical consensus on all clause requirements was reached in February 2026, with only finalizations of informative sections such as Annex A remaining before the FDIS is issued.

This revision updates a standard that has not been substantially revised since 2015. For organizations already certified to ISO 9001:2015, the changes are targeted and manageable. The standard does not introduce a new structure, a new process model, or dramatically new compliance obligations.

The ISO 9001:2026 Revision Timeline

Understanding where the standard sits in its development cycle helps quality teams plan transition timing accurately.

May 2021: ISO/TC 176/SC 2 votes to confirm ISO 9001:2015 without revision.

July 2023: ISO announces an immediate reversal and begins the revision process following re-evaluation.

August 2025: DIS published to ISO member bodies for review and ballot. Source: ISO.org

December 2025: Member countries vote to approve the DIS with a 97% approval rate.

February 2026: Full technical consensus reached on Clauses 1-10 at the meeting in Mexico City, attended by 83 experts from 42 countries.

June 2026: Final Draft International Standard (FDIS) expected.

September 2026: ISO 9001:2026 publication targeted. Three-year transition window opens.

Mid-2027: First ISO 9001:2026 certificates expected, after certification bodies complete their own accreditation process (typically 9-12 months post-publication).

September 2029: Transition deadline. ISO 9001:2015 retires. All certified organizations must hold a current ISO 9001:2026 certificate.

One critical planning note: ISO 9001:2026 certificates will not be available immediately upon standard publication. Certification bodies must first be trained and accredited to audit against the new standard by their national accreditation bodies. This process typically takes 9-12 months, meaning the earliest organizations can reasonably expect to receive an ISO 9001:2026 certificate is mid-2027.

What Is Changing in ISO 9001:2026: The Confirmed Clause Updates

The DIS confirms that ISO 9001:2026 is a targeted evolution, not an overhaul. The clause structure (1-10) stays the same. The Annex SL high-level structure, which aligns ISO 9001 with other ISO management system standards like ISO 14001 and ISO 45001, is maintained. The core process approach and fundamental requirements carry forward from 2015.

Five confirmed changes affect specific clauses. Each one has direct implications for how quality teams document, train, and manage their systems.

Change 1 – Clause 4.1: Climate Change Is Now a Required Context Factor

The February 2024 amendment to ISO 9001:2015, which added climate change as a consideration in the organization's context, has been formally incorporated into ISO 9001:2026 as part of Clause 4.1. This requirement is not new for organizations that adopted the 2024 amendment. For those that did not, it represents the most immediately actionable change in the 2026 revision.

Clause 4.1 requires organizations to determine the external and internal issues relevant to their purpose that affect their ability to achieve their QMS objectives. Climate change now sits explicitly within that scope. Organizations must consider whether climate-related risks or conditions affect their operations, supply chain, customer base, or regulatory environment.

The standard does not prescribe a carbon reduction program or environmental management plan. That level of expectation belongs to ISO 14001. What ISO 9001:2026 adds is the requirement to acknowledge climate change as part of the strategic context that shapes your QMS.

Change 2 – Clause 5.1.1: Leadership Must Drive Quality Culture and Ethical Behavior

Clause 5.1.1, which covers top management responsibilities, now explicitly requires leaders to promote and demonstrate a quality culture and ethical behavior within the organization. The 2026 DIS adds new guidance on how this demonstration can be evidenced.

This change has practical audit implications. Under ISO 9001:2015, leadership commitment was largely evidenced through documented policies, objectives, and resource allocation decisions. Under ISO 9001:2026, audits will increasingly look for evidence that leadership actively promotes quality culture, not just approves quality documents.

Quality teams preparing for the transition should begin documenting leadership behaviors: communications on quality from the executive level, participation in quality reviews, visible involvement in CAPA decisions, and messaging that reinforces ethical conduct across the organization. These activities likely already occur in well-run organizations. The change is that they must now be demonstrably connected to the quality system.

Change 3 – Clause 5.2: Quality Policy Must Reflect Strategic Direction

The quality policy requirements in Clause 5.2 are strengthened. Under ISO 9001:2026, the quality policy must explicitly "take into account the context of the organization and support its strategic direction." This creates a tighter and more auditable link between the quality policy and the broader business strategy.

For organizations whose quality policy is a static, generic commitment statement that has not been reviewed alongside business strategy changes, this represents a gap worth addressing. The policy must visibly reflect where the organization is going, not just where it was when the policy was written.

Change 4 – Clause 6.1: Risk and Opportunity Management Restructured into Sub-Clauses

ISO 9001:2026 reorganizes Clause 6.1 into three sub-clauses: 6.1.1, 6.1.2, and 6.1.3. This restructuring separates the determination of risks and opportunities from the planning of actions to address them, improving the clarity and readability of the requirement.

For organizations already maintaining a Risk Register and documenting risk-based thinking as required by ISO 9001:2015, the practical change is minimal. The underlying obligation to identify, assess, and address risks and opportunities does not expand. The restructuring provides clearer delineation between those activities, which should make the clause easier to audit and easier to implement for organizations earlier in their QMS maturity.

The new Annex A, a first in ISO 9001's history, provides significantly expanded guidance on both risk and opportunity management, giving organizations more reference material for demonstrating conformance.

Change 5 – Clause 7.3: Awareness of Quality Culture and Ethical Behavior

Clause 7.3, which covers awareness, gains a new requirement: employees must understand quality culture and ethical behavior as part of their awareness training. This connects directly to the leadership changes in Clause 5.1.1.

Under ISO 9001:2015, Clause 7.3 required employees to be aware of the quality policy, their contribution to QMS objectives, and the implications of not conforming. ISO 9001:2026 adds quality culture and ethical behavior to that list.

For quality teams, this means training programs and competency records need to document that these concepts are addressed, not just technical procedure compliance. Audit finding categories under this clause will likely expand accordingly.

What Is Not Changing in ISO 9001:2026

Given the speculation that preceded the DIS, it is worth being direct about what the revision does not include.

No new digital or AI requirements. Despite widespread expectation that ISO 9001:2026 would formally address artificial intelligence, digitalization, or technology governance, the DIS includes no significant new requirements in these areas. The standard remains technology-neutral.

No major supply chain resilience requirements. Supply chain risk management expectations have not been substantially expanded beyond the Clause 8.4 requirements already present in ISO 9001:2015.

No new sustainability obligations. Beyond the climate change context requirement in Clause 4.1, the standard does not add ESG or broader sustainability requirements. ISO 14001 remains the appropriate framework for environmental management.

No new service sector requirements. Service-specific guidance expected by some national bodies did not materialize in the DIS.

The core process approach, the Plan-Do-Check-Act model, and the fundamental requirements for documented information, customer focus, and continual improvement all carry forward from 2015 without major alteration.

What Happens to Your ISO 9001:2015 Certificate

ISO 9001:2015 certifications remain fully valid through the transition period, which ends in September 2029. No immediate action is required for currently certified organizations.

The transition path works as follows: after ISO 9001:2026 is published in September 2026, certification bodies will spend approximately 9-12 months completing their own accreditation to audit against the new standard. During this period, your ISO 9001:2015 certification remains valid and active. The first ISO 9001:2026 audits and certificates are expected no earlier than mid-2027.

Organizations have until September 2029 to complete their transition audit and receive an ISO 9001:2026 certificate. After that date, ISO 9001:2015 certificates expire and will no longer be recognized as valid certification.

You cannot hold both certifications simultaneously. An ISO 9001:2026 certificate supersedes and replaces the ISO 9001:2015 version.

Gap Analysis: What Quality Teams Should Do Right Now

The confirmation of the DIS and the approach of the FDIS gives quality leaders enough information to begin a structured transition gap analysis. Waiting until the FDIS or final publication in September 2026 delays preparation unnecessarily.

Review Clause 4.1 for climate change. Determine whether your current external context analysis addresses climate change as a relevant factor. If it does not, begin the process of integrating it into your context review documentation and your process audit schedule.

Audit leadership communications and behaviors. Identify how top management currently demonstrates quality culture and ethical behavior. Document existing leadership activities that support quality, and assess whether gaps exist between what currently happens and what Clause 5.1.1 will require as auditable evidence.

Review your quality policy. Assess whether the current quality policy explicitly references your organization's strategic direction and context. If it is a generic statement, begin the revision process now. Policy changes under a QMS require document control and communication to relevant personnel, so allow adequate lead time.

Map your risk management documentation. Confirm your risk register and risk-based thinking documentation align with the three-part structure of the revised Clause 6.1. The restructuring may require only minor documentation reorganization rather than a process overhaul.

Update employee awareness training. Identify whether current training programs explicitly address quality culture and ethical behavior as awareness topics. Add these elements to training content and begin capturing records of their completion.

Review Supplier Quality Management (SQM) processes. Although Clause 8.4 does not dramatically change, the emphasis on supply chain oversight in the DIS context suggests auditors will examine supplier controls more closely. Confirm your supplier qualification, monitoring, and performance review processes are documented and current.

The First Guidance Annex in ISO 9001 History

One notable structural addition in ISO 9001:2026 is Annex A: an informative guidance annex included in the standard for the first time. Previous editions of ISO 9001 included only normative requirements, leaving organizations to interpret application through external guidance documents and certification body explanations.

The new Annex A provides expanded guidance particularly on risk and opportunity management, quality culture, and how leadership expectations can be evidenced. While the annex is informative rather than normative, meaning it does not create new compliance requirements, it will meaningfully influence how auditors interpret and assess conformance in these areas.

Quality leaders should incorporate Annex A into their transition planning once the FDIS is published, as it will provide the clearest signal of auditor expectations under the new standard.

How an Integrated eQMS Supports ISO 9001:2026 Transition

The changes in ISO 9001:2026 place more emphasis on evidence, documentation linkage, and leadership visibility than the 2015 version. Organizations still managing their quality systems across disconnected spreadsheets, shared drives, and email threads will face the most friction in demonstrating conformance to the new requirements, particularly the leadership culture expectations of Clause 5.1.1 and the expanded awareness documentation requirements of Clause 7.3.

An integrated eQMS gives quality teams a single, structured environment where leadership activities, training records, risk registers, audit trails, and process change notifications all reside in one validated system. When an auditor asks for evidence that employees completed quality culture awareness training, or that leadership reviewed the risk register after a significant business change, the data is accessible and time-stamped rather than assembled manually from across the organization.

Cloudtheapp's AI-powered eQMS is built to support the full clause structure of ISO 9001, ISO 13485, and the FDA QMSR, with pre-configured applications for risk management, supplier quality, internal audits, management review, document control, and employee training. Organizations using Cloudtheapp can begin mapping their existing system to the ISO 9001:2026 clause changes now, identifying documentation gaps and updating quality policy and awareness training content before the final standard is published.

Book a free demo to see how Cloudtheapp supports ISO 9001 compliance through every revision and audit cycle.

Conclusion

ISO 9001:2026 is an evolutionary update. The clause structure, process approach, and core requirements of ISO 9001:2015 all survive into the new edition with targeted refinements rather than wholesale changes. Quality teams that understand the confirmed changes, specifically in Clauses 4.1, 5.1.1, 5.2, 6.1, and 7.3, can begin gap analysis and transition planning today, well ahead of the September 2026 publication and the September 2029 compliance deadline.

The organizations that face the smoothest transitions are not those that wait for the final standard to act. They are the ones that build strong, documented, evidence-rich quality systems now, treating the 2015 requirements as a solid foundation for what 2026 will require rather than a box to check before the next revision cycle begins.

This post created by and appeared first on Cloudtheapp

Choosing quality management software for a regulated industry organization requires evaluating regulatory alignment, configurability, validation documentation, deployment model, and vendor expertise. The right platform reduces compliance risk, accelerates audit readiness, and scales with your organization as regulatory demands evolve.

What Is Quality Management Software?

Quality management software is a digital platform that helps organizations document, manage, and improve the processes that determine product and service quality. In regulated industries, quality management software is the operational backbone of compliance with ISO 9001, ISO 13485, FDA 21 CFR Part 820, and GMP regulations.

At its most functional level, quality management software replaces manual, paper-based processes with automated workflows, electronic approvals, traceable records, and real-time performance data. It connects quality events — deviations, CAPAs, change requests, complaints, supplier issues — into a single, coherent quality system where every record is controlled, searchable, and audit-ready.

According to Polaris Market Research, the global quality management software market was valued at $11.05 billion in 2024 and is projected to grow at 11.7% CAGR through 2034. Demand is driven by tightening regulatory requirements, digital transformation initiatives, and the proven operational ROI of modern quality platforms.

Why the Wrong QMS Can Cost You

The choice of quality management software has direct implications for regulatory standing, product quality, and operational efficiency. An inadequate system — or one not built for your industry — creates multiple risk categories:

Validation burden. Some platforms require extensive customer-side validation before regulated use. This consumes months of quality engineering time and delays your go-live significantly.

Configuration rigidity. Generic platforms designed for broad markets often cannot accommodate industry-specific workflows, regulatory forms, or data structures. Teams end up working around the system rather than with it.

Upgrade disruption. Legacy platforms with complex, infrequent upgrade cycles require internal resources to manage each release. In regulated environments, each upgrade may require re-validation, adding cost and risk.

Audit exposure. Systems that lack immutable audit trails, proper version control, or 21 CFR Part 11-compliant electronic signatures create documentation gaps that surface directly in FDA and ISO audits.

Scalability limits. Point solutions designed for one site or one quality process fail to support growth across products, sites, and geographies without significant additional investment.

7 Criteria for Choosing Quality Management Software

1. Regulatory Alignment and Pre-Validation

Your quality management software must be aligned with the specific regulations governing your industry. For medical devices: ISO 13485 and FDA 21 CFR Part 820 (QMSR). For pharmaceuticals: 21 CFR Parts 210 and 211, GMP. For food and beverage: ISO 22000/FSSC 22000.

Pre-validated platforms come with a complete Computer System Validation (CSV) package including IQ/OQ/PQ documentation, traceability matrices, and test scripts. This reduces your validation effort to execution rather than creation.

2. No-Code Configurability

Every organization has unique quality processes. Quality management software should adapt to your workflows through no-code configuration rather than forcing your processes into rigid templates.

No-code platforms let quality managers create new forms, modify approval workflows, and build applications without developer involvement. This reduces implementation timelines from months to weeks and enables continuous improvement of your quality system without IT dependency.

3. Integrated Quality Applications

A complete quality management software platform integrates all quality processes in a single environment: document control, deviation CAPA, change management, training, audits, complaints, batch records, risk management, and supplier quality management.

Siloed point solutions create traceability gaps between quality events. A CAPA opened from a deviation should link directly to the original deviation report, the root cause investigation, and the effectiveness verification record. This cross-process traceability is only possible in an integrated platform.

4. AI and Analytics Capabilities

Modern quality management software incorporates AI to identify recurring deviation patterns, surface emerging risks, and accelerate CAPA root cause investigations. Built-in analytics dashboards provide quality leadership with real-time visibility into open quality events, training compliance status, audit schedules, and system-wide trends.

Organizations that rely on manual reporting or periodic data exports miss the in-period signals that enable proactive quality management.

5. Cloud-Native Architecture

Cloud-native quality management software on established infrastructure like AWS delivers the reliability, security, and scalability that regulated industries require. Cloud platforms eliminate on-premise hardware costs, provide disaster recovery by design, and scale as your organization grows.

6. Seamless Validated Upgrades

Regulatory requirements evolve continuously. Your quality management software must keep pace without requiring your team to manage upgrade projects.

Look for vendors that push validated, automatic updates to all customers simultaneously. This ensures your system stays compliant as standards change, without the cost and disruption of manual upgrade cycles.

7. Vendor Domain Expertise and Support

In regulated industries, implementation support requires deep knowledge of GxP, FDA, and ISO expectations — not just general software knowledge. Evaluate the vendor's industry experience, implementation methodology, and ongoing support model before committing.

Unmatched customer support — from onboarding through daily operations — separates platforms that deliver long-term value from those that become frustrating IT projects.

Industry-Specific Considerations

Pharmaceutical and Biotech. Look for platforms with built-in support for batch records, annual product reviews, deviation management, and GMP-aligned document control. Data integrity compliance with 21 CFR Part 11 and EU Annex 11 is non-negotiable.

Medical Devices. Platforms must support design controls, risk management (ISO 14971), supplier quality management, and the post-market surveillance requirements introduced by EU MDR and the FDA's updated QMSR. Traceability from design through production is essential for 510(k) submission readiness.

Food and Beverage. HACCP, supplier qualification, FSSC 22000, and traceability from ingredient to finished product are the core quality requirements. Quality management software in this space must handle high-volume, batch-based production with rapid audit response capabilities.

Manufacturing. Non-conformance management, calibration and maintenance records, inspection management, and ERP integration are the primary quality software requirements for discrete and process manufacturers.

Red Flags to Avoid

Watch for these warning signs when evaluating quality management software:

• The platform requires customers to perform full IQ/OQ/PQ validation from scratch with no vendor-provided package.
• Configuration requires coding or professional services for basic workflow changes.
• Upgrade cycles are annual or biannual, with known disruption and re-validation requirements.
• The platform lacks a native, immutable audit trail and 21 CFR Part 11-compliant electronic signature capability.
• The vendor has limited regulated industry experience.
• Multi-environment configuration management (Dev, QA, Prod) is unavailable or cost-prohibitive.

Cloudtheapp: Purpose-Built Quality Management Software

Cloudtheapp checks every criterion above. It is an AI-powered, no-code, cloud-native quality management software platform purpose-built for pharmaceutical, medical device, biotech, food and beverage, and manufacturing organizations.

The platform includes 45+ pre-built applications covering every core quality process in a single FDA-validated environment on AWS. No-code designers and AI-driven configuration let quality teams build and deploy workflows in minutes without coding. Validated updates are automatic, free, and delivered to all customers simultaneously.

Cloudtheapp supports multi-environment configuration management (Dev, QA, Production) with single-click deployment in under 3 seconds. The platform is compliant with FDA 21 CFR Part 820 (QMSR), ISO 13485, ISO 9001, ISO 22001, and 21 CFR Part 11 — and a complete validation package accompanies every platform update.

Request a demo or start a 30-day free trial to see how Cloudtheapp delivers quality management software built for the demands of regulated industries.

Conclusion

Choosing quality management software is one of the most consequential technology decisions a regulated industry organization makes. The right platform accelerates compliance, reduces audit risk, and gives quality teams the tools they need to manage quality at scale.

The wrong platform means months of validation work, inflexible workflows, and systems that fall behind evolving regulatory requirements.

Use the seven criteria above to evaluate platforms objectively, and prioritize vendors with proven regulatory domain expertise, pre-validated platforms, and no-code configurability designed for the pace of modern quality management.

This post created by and appeared first on Cloudtheapp